A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases | MicrobiomeTrials← Back to trialsNCT06786338
A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-06-06Est. Completion: 2026-12-29
Enrollment target: 45 participants Locations- Peking University First Hospital, Beijing, China
- Peking University People's Hospital, Beijing, China
- The Third Xiangya Hospital of Central South University, Changsha, China
- Sichuan Provincial People's Hospital, Chengdu, China
- Guizhou Provincial People's Hospital, Guiyang, China
- The affiliated hospital of Guizhou medical university, Guiyang, China
- The first affiliated hospital, Zhejiang university school of medicine, Hangzhou, China
- Huashan hospital, Shanghai, China
- Northern Jiangsu People's Hospital, Yangzhou, China
- General hospital of ningxia medical university, Yinchuan, China
- Henan Provincial People's Hospital, Zhengzhou, China
Other microbiome trials you might be interested in
Primary Immunoglobulin A Nephropathy (IgAN)
The study is an open-label, single arm, multicenter, Phase III study to determine proteinuria reduction, pharmacokinetic…
Madera, United StatesEst. completion Jun 28, 2030
Immunoglobulin A (IgA) Nephropathy
The purpose of the study is to evaluate safety, tolerability, and preliminary effectiveness following administration of …
Miami, United StatesEst. completion Sep 2028
Phase 3
Recruiting
Immunoglobulin A Nephropathy
The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of povetacicept in participants…
Multiple LocationsEst. completion Dec 28, 2029